Since my last blog post, I've raised an additional $967.78 and I've run an additional 50 miles!
As of today:
Amount raised: $2,417.78
Total distance run: 162 miles
Thank you so much to everyone who has supported my efforts up to this point, either through donations and/or words of encouragement.
I'm still having a lot of trouble with my right knee. It has stopped hurting while I run, but, especially after my long runs, it swells and becomes painful and tight. I've been to physical therapy and am trying some exercises - along with my ice and ibuprofen regimen. Friends have encouraged me to have an MRI, but I'm afraid that I will be told not to run...and that's NOT an option. Stubbornness comes from both sides of my family. :-)
To date, my longest run has been 10.23 miles! It's hard to believe that I've gone from 0 to 10.23 miles in a little over 10 weeks. Only 6 more weeks and I'll be running 13.1 miles!
My run with the best scenery was just last week, on Thanksgiving Day, at Keeneland here in Lexington. While we didn't run on the race track during the "Thoroughbred Classic 5K", we ran on the grounds what has to be one of the most beautiful horse racing venues in the country.
The Orange Leaf fundraiser was a success - earning over $67 for The Leukemia and Lymphoma Society. That's over $271 of yogurt consumed - 553 ounces (if I'm doing the math correctly)! Quite a few of my friends were thankful that I gave them a reason to eat yummy frozen yogurt - for a good cause. :-)
My current fundraiser is a Pampered Chef online/catalog party, of which 15% of the sales goes to The Leukemia and Lymphoma Society. You can visit the online store here:
http://www.pamperedchef.biz/juliepetroze?page=host-search-results&showId=3419071
The last day to order is December 18th, with products guaranteed to be delivered by Christmas. Please visit the site and consider ordering Pampered Chef items for friends and/or family.
Thanks again to all of my friends and supporters. This journey has been more worthwhile because of you!
If you know anyone who has been affected by Leukemia, Lymphoma or another form of cancer, please feel free to share my journey with them.
http://pages.teamintraining.org/ky/pfchanges12/GoJulieG
GO TEAM!!
--------------------------
Keeping reading!! The Leukemia and Lymphoma Society is doing great things!
Below is an example of a drug that has been FDA-approved because of research funded by LLS, but has been picked up for clinical trials to treat patients with many other cancers.
Thanks to LLS research funding, immunomodulatory (IMiD) drugs are helping many blood cancer patients.
Thalidomid® is FDA-approved for newly diagnosed myeloma patients and Revlimid® is approved for myeloma patients who have undergone at least one prior treatment.
LLS-funded investigators continue developing these drugs for patients with myeloma, MDS, CLL, Hodgkin lymphoma and NHL, acute myeloid leukemia (AML) and myeloproliferative disorders.
Thalidomid and Revlimid are helping other patients too.
Other clinical trials are ongoing for patients with AIDS-related Kaposi sarcoma, and for patients with liver, kidney, ovarian, prostate, pancreatic and colorectal cancers.
In addition:
Two-Drug Combo May Help Hard-to-Treat Leukemia
A combination of two drugs -- the chemotherapy drug Fludara and the biologic drug Campath -- may allow people with hard-to-treat chronic lymphocytic leukemia (CLL) to live longer.
A combination of two drugs -- the chemotherapy drug Fludara and the biologic drug Campath -- may allow people with hard-to-treat chronic lymphocytic leukemia (CLL) to live longer.
Ruxolitinib
On November 16, 2011, the U. S. Food and Drug Administration approved ruxolitinib (Jakafi oral tablets, Incyte Corporation) for the treatment of intermediate and high risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Results of two randomized controlled trials in patients with intermediate or high risk myelofibrosis comparing ruxolitinib to placebo (Study 1) or to best available therapy (Study 2) were the basis of approval.
On November 16, 2011, the U. S. Food and Drug Administration approved ruxolitinib (Jakafi oral tablets, Incyte Corporation) for the treatment of intermediate and high risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Results of two randomized controlled trials in patients with intermediate or high risk myelofibrosis comparing ruxolitinib to placebo (Study 1) or to best available therapy (Study 2) were the basis of approval.
